The short answer
Berberine has not been shown to change alogliptin exposure or effectiveness. Human enzyme findings with other drugs cannot predict this largely renally eliminated medicine’s response.
What this answer covers
Oral berberine preparations; extract composition and dose vary.
- Supplement or preparation
- Berberine
- Medication ingredient
- alogliptin
The enzyme study used probe drugs
Repeated berberine altered several enzyme-activity measures in healthy volunteers, including CYP2D6, CYP2C9 and CYP3A4. Alogliptin was not tested.
Alogliptin has limited metabolism
Most alogliptin is excreted unchanged in urine. CYP2D6 and CYP3A4 contribute only to its limited metabolism, so a measured midazolam or other probe-drug change cannot be treated as an alogliptin percentage change.
The exact clinical effect remains uncertain
The enzyme study did not measure alogliptin absorption, blood exposure, glucose response or treatment failure. A plausible laboratory mechanism alone does not establish this pair’s direction or size.
Review the product and glucose response
Discuss starting or stopping the supplement with the diabetes team, and follow the prescribed monitoring plan. Do not change alogliptin yourself or assume a short spacing gap prevents a glucose effect. Kidney function, rather than a botanical enzyme theory alone, is central to its dosing.
Evidence and practical considerations
Absorption & effectiveness
No verified exact alogliptin clinical interaction. Original botanical preparations, other treatment regimens and null findings cannot establish the stated exposure/effectiveness or hypoglycemia claim.
- Exact scope
- Oral berberine preparations; extract composition and dose vary. with Oral alogliptin RxCUI 1368001 IN supplied as benzoate; limited metabolism and renal elimination retained.
- Medication form and route
- oral medication; oral supplement
What remains uncertain
- No unmeasured event rate, imported CYP effect size or arbitrary dose adjustment.
Factors that may matter: Preparation; Kidney function; Other glucose-lowering medicines.
Read the supporting source summaries
Source 1: current product label
dailymed.nlm.nih.gov · Source check Sep 10, 2026
Population: Patients prescribed oral alogliptin
DPP-4 inhibition produces glucose-dependent effects. Most dose is excreted unchanged in urine; CYP metabolism is limited. With or without food. Hypoglycemia precautions especially with insulin/secretagogues; renal function determines dosing.
How this applies: Exact alogliptin active-moiety bridge from current benzoate tablet label.
Not metformin/pioglitazone combination products. No exact botanical interaction rate or automatic nutrient requirement. Limited CYP role precludes simple probe-drug transfer.
Source 2: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: 329 treatment-naive type 2 diabetes participants.
Alogliptin improved glycemic control; hypoglycemia and overall adverse-event proportions were similar across active and placebo groups.
How this applies: Exact alogliptin relevance limited by original exposure and endpoint.
Monotherapy does not establish supplement co-use safety or zero hypoglycemia.
Source 3: original human study
pubmed.ncbi.nlm.nih.gov · Source check Sep 10, 2026
Population: Healthy male participants.
Repeated berberine inhibited CYP2D6, CYP2C9 and CYP3A4 probe activities; other probe pharmacokinetic results were not significantly different.
How this applies: Exact alogliptin relevance limited by original exposure and endpoint.
No alogliptin; probe-drug effect sizes cannot be assigned to a mostly renally excreted medicine. Abstract only.
Research assessment: · Open full citations ↗
Review and change history
- Publication status
- Published research summary
- Clinical review
- Not yet recorded
| Date | Update |
|---|---|
| Article prepared | |
| Prepared exact alogliptin article separating renal disposition, glucose effects and general husk timing. | |
| Research summary published |
Article revision: 08e35ebc31452361
This guide brings together the evidence records used by our interaction checker. Each finding retains its own preparation limits, research date, and source summaries.
Full citations require verification. Reading this answer and the source summaries does not.
Taking other supplements or medications?
Use the checker to explore your other combinations. Ask a pharmacist to review the exact products, amounts and medical conditions in your complete list.
Open the interaction checkerInformation, not medical advice. Do not change prescribed treatment based on this guide.